Login / Signup

The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process.

Mehul BhattacharyyaLarry E MillerAnna L MillerRuemon Bhattacharyya
Published in: Expert opinion on biological therapy (2024)
Keyphrases
  • duchenne muscular dystrophy
  • transcription factor
  • muscular dystrophy
  • drug administration